INTRODUCTION
============

Activity-dependent gene transcription is functionally relevant for animals to acquire information and adapt to the environment. One major ion involved in transducing neuronal activity and regulating transcription is calcium (Ca^2+^). Ca^2+^ influx through voltage-gated Ca^2+^ channels (VGCCs) serves as a key transducer coupling changes in cell surface membrane potential with local intracellular Ca^2+^ pathways. Among the L-type VGCCs (L-VGCCs), Ca~V~1.2 is also expressed in the organ of corti ([@B16]; [@B54]) and the brain ([@B6]; [@B62]). In the brain, Ca~V~1.2 is assumed to participate in altering synapse efficacy through transcriptional control of brain-derived neurotrophic factor (BDNF; [@B48]; [@B62]). The BDNF transcription is highly responsive to neural activity. It is up-regulated by learning ([@B17]; [@B27]), physical exercise ([@B33]), and kindling or kainate-induced seizures ([@B10]). The L-VGCCs contribute to the asynchronous release of neurotrophins like BDNF from individual vesicles ([@B3]; [@B21]), which is most probably Ca~V~1.2 dependent ([@B21]). Accordingly, Ca^2+^ entering the cell, either through Ca~V~1.2 or *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptors can differentially activate the BDNF promoter IV ([@B60]), which controls one of the eight untranslated 5′BDNF exons (exon I-VIII) upstream of a common 3′BDNF exon IX that encodes the BDNF protein ([@B1]). The BDNF transcribed from exon IV is also expressed in the inner ear ([@B40]) and is changed after ototoxic drug treatment through Ca^2+^-responsive elements such as CaRF1 in cochlear neurons ([@B45]). It is also found that BDNF is up-regulated following auditory trauma ([@B50]). These observations may be related to the contrasting roles of BDNF previously described in the intact or injured cochlea ([@B63]).

On the one side, BDNF plays a crucial role to upgrade complexity of the inner hair cell (IHC) synapse, including maintenance of mature IHC number of synaptic ribbons, electron-dense presynaptic specializations that tether synaptic vesicles for exocytosis at the active zone ([@B15]; [@B31]; [@B41]) in mice ([@B63]) and zebrafish ([@B30]). On the other side, BDNF is harmful when acoustic overstimulation damages the mature system ([@B63]). As IHC ribbons are crucial for precision of sound processing ([@B4]) and IHC ribbon loss and deafferentation after acoustic trauma is discussed in the context of age-dependent hearing loss, hyperacusis, and tinnitus ([@B22]; [@B26]; [@B46]), the elucidation of the molecular basis of these effects is of crucial clinical relevance. As Ca~V~1.2 ([@B13]) and BDNF up-regulation ([@B8]; [@B52]) is also discussed in the context of pain, our findings may contribute to the understanding of sensory pathology beyond the auditory field.

To elucidate to what extent Ca~V~1.2 might participate in the described roles of BDNF in the healthy and injured cochlea, we analyzed Ca~V~1.2 function following conditional deletion of Ca~V~1.2 in the auditory system. This approach is essential as mice globally lacking Ca~V~1.2 die *in utero* before day 15 post-coitum ([@B43]). We conditionally inactivated Ca~V~1.2 in the auditory system using the same Cre transgenic mouse line as used for deletion of BDNF ([@B63]). As feedback loops from higher auditory centers, known as the corticofugal pathway ([@B14]), have been shown to modulate directly efferent feedback along the descending auditory pathway as well as the IHC in a frequency-specific way ([@B58]), we studied mice with an inactivation of Ca~V~1.2 in the superior olivary complex (SOC) that represent the second central auditory processing center in the ascending auditory pathway, using the Cre expression under the Egr2 promoter ([@B53]; [@B39]).

Both Ca~V~1.2^Pax2^ and Ca~V~1.2^Egr2^ conditional knock-out (KO) mice were viable and thus could be analyzed for hearing capability, sound processing along the ascending auditory pathway, and sensitivity to noise exposure. We demonstrate here that Ca~V~1.2 is neither required in the cochlea nor in the SOC for normal IHC or outer hair cell (OHC) function, thus suggesting that BDNF function in normal IHC physiology ([@B63]) does not depend on Ca~V~1.2. In contrast, loss of Ca~V~1.2 in the cochlea, but not in the SOC, partially mimics the described harmful BDNF effect during acoustic trauma, a feature that could be linked to reduced BDNF mRNA levels in cochlear tissue of Ca~V~1.2^Pax2^ mice. The results are discussed in the context of a role of L-type Ca^2+^ channels for BDNF release during cochlear injury.

MATERIALS AND METHODS {#s1}
=====================

Care and use of animals and the experimental protocol were reviewed and approved by animal welfare commissioner and the regional board for scientific animal experiments in Tübingen, Germany.

GENERATION OF CONDITIONAL KNOCK-OUT MICE
----------------------------------------

The conditional Ca~V~1.2 knock-out mice Ca~V~1.2^Pax2^ KO were generated by breeding mice carrying the floxed Ca~V~1.2 allele (L2; [@B43]) with mice expressing Cre under control of Pax2 regulatory regions ([@B34]) carrying one floxed Ca~V~1.2 allele (L1; [@B43]), resulting in cochlea-specific Ca~V~1.2^Pax2^ KO mice (Ca~V~1.2 L1/L2, Pax2::Cre) and control animals (Ca~V~1.2+/L2, Pax2::Cre). Besides the cochlea, Ca~V~1.2 was deleted in the dorsal cochlear nucleus (DCN), inferior colliculus (IC), and the cerebellum in these mice ([@B34]; [@B63]).

The Ca~V~1.2^Egr2^ KO mice were generated by breeding mice carrying floxed Ca~V~1.2 alleles (L2; [@B43]) with mice carrying one Ca~V~1.2 KO allele (L1; [@B43]) and expressing Cre from one allele of the Egr2 locus ([@B53]), which mediates recombination in rhombomeres 3 and 5 of the embryonic neural tube, allowing genetic manipulation of neuronal populations such as the lateral superior olive (LSO) and medial nucleus of the trapezoid body (MNTB) but not in the cochlea, obtaining a specific knock-out in the LSO and MNTB ([@B53]; [@B36]; [@B39]).

HEARING MEASUREMENTS: AUDITORY BRAINSTEM RESPONSE AND DISTORTION PRODUCT OTOACOUSTIC EMISSION
---------------------------------------------------------------------------------------------

Auditory brainstem response (ABR), evoked by short-duration sound stimuli, represents the summed activity of neurons in distinct anatomical structures or nuclei along the ascending auditory pathway ([@B5]) and is measured by averaging the evoked electrical response recorded *via* subcutaneous electrodes. The ABR to click and pure tone stimuli and the cubic 2 × *f*1 - *f*2 distortion product of the otoacoustic emission (DPOAE) for *f*2 = 1.24 × *f*1 and L2 = L1 - 10 dB were recorded in anesthetized mice aged 6--9 weeks. All physiological recordings were performed under anesthesia \[75 mg/kg ketamine hydrochloride (Ketavet, Pharmacia, Pfitzer, Karlsruhe, Germany), 5 mg/kg xylazine hydrochloride (Rompun 2%, Bayer Leverkusen, Germany), 0.2 mg/kg atropine (Atropinsulfat B. Braun, Melsungen, Germany)\] in a soundproof chamber (IAC, Niederkrüchten, Germany) as previously described ([@B12]). In short, ABR thresholds were determined with click (100 μs), and pure tone (2--45.3 kHz, 3 ms duration) stimuli. OHC function was assessed by the DPOAE thresholds evoked by stimuli at various frequencies (*f*2 = 4--32 kHz with half-octave steps) and growth function of the DPOAE evoked by *f*2 = 11.3 kHz.

NOISE EXPOSURE
--------------

For noise exposure, animals were exposed to broadband noise (4--16 kHz, 120 dB sound pressure level (SPL) for 1 h) as previously described ([@B12]) while under anesthesia (see above), and supplemental doses of anesthetics were administered subcutaneously every 20 min. Sham-exposed animals were anesthetized and placed in the reverberating chamber, but not exposed to acoustic stimulus (i.e., the speaker remained turned off). In noise-exposed mice, the degree of the ABR threshold shift was measured more than 7 days after noise exposure, when noise-induced permanent threshold shift (PTS; [@B24]; [@B38]) have settled and a recovery from damage is no longer expected. The sham-exposed animals have completely normal hearing.

TISSUE PREPARATION
------------------

For immunohistochemistry, cochleae were isolated, fixed by immersion in 2% paraformaldehyde, 125 mM sucrose in 100 mM phosphate-buffered saline, pH 7.4, for 2 h, and then decalcified for 45 min in RDO rapid decalcifier (Apex Engineering Products Corporation, Aurora, IL, USA) as previously described ([@B20]; [@B63]; [@B46]), cryosectioned at 10 μm, mounted on SuperFrost\*/plus microscope slides at -20°C.

For RNA and proteins isolation, cochleae and different brain regions were dissected with small forceps and immediately frozen in liquid nitrogen and stored at -80°C until use.

RNA ISOLATION, cDNA SYNTHESIS, AND REAL-TIME PCR
------------------------------------------------

For real-time polymerase chain reaction (PCR) analysis, RNA from mouse cochlea was isolated using the RNeasy mini kit (QIAGEN, Hilden, Germany) following the manufacturer's instructions. After reverse transcription using Sensiscript RT kit (QIAGEN), real-time PCR was performed using the iCycler iQ detection system (Bio-Rad, Munich, Germany). The real-time PCR reaction was set up following the manufacturer's instruction (QuantiFast SYBR Green, QIAGEN). The following primers were used: BDNF quantification, for 5′-GAAGCAAACGTCCACGGACAA-3′ and rev 5′-AACCTTCTGGTCCTCATCCAG-3′; β-actin quantification, used as housekeeping gene, for 5′-GAATCCTGTGGCATCCATGA-3′ and rev 5′-CATCTGCTGGAAGGTGGACA-3′. The PCR program, according to the manufacturer's instructions, included an initial activation step at 95°C for 5 min, followed by 40 cycles of a 10-s lasting denaturing step at 95°C and a 30-s combined annealing/extension step at 60°C; all temperature transition rates were 1--3°C/s. At the end of each cycle, the fluorescence emitted by SYBR Green was measured. At the end of the PCR reaction, samples were subjected to a temperature ramp (from 70 to 95°C, 2°C/s) with continuous fluorescence monitoring for melting curve analysis. For each PCR product, a single narrow peak was obtained by melting curve analysis at the specific temperature. Each sample was assayed in triplicate and the analysis was performed with Gene Expression Macro (version 1.1, Bio-Rad, Munich, Germany). Samples containing no template were used as negative controls in each experiment. Data were normalized to the housekeeping gene expression level and presented as a percentage of the expression relative to the control ± standard deviation (SD).

IMMUNOHISTOCHEMISTRY
--------------------

For immunohistochemistry, mouse cochlear sections were stained as previously described ([@B50]; [@B63]; [@B46]). The CtBP2/RIBEYE, mouse (BD Transduction Laboratories, USA); Otoferlin, rabbit ([@B42]); and Ca~V~1.2, rb ([@B18]) were used as primary antibodies. For double labeling studies, both antibodies were simultaneously incubated for identical time periods. Sections were viewed, as previously described ([@B59]), using an Olympus BX61 microscope equipped with epifluorescence illumination. Images were acquired using an Olympus XM10 CCD monochrome camera and analyzed with cellSens Dimension software (OSIS GmbH, Munster, Germany). To increase spatial resolution, slices were imaged over a distance of 15 μm within an image-stack along the *z*-axis (*z*-stack) followed by 3-dimensional deconvolution using cellSens dimension built-in algorithm.

NORTHERN BLOT
-------------

The mRNA isolation was performed using the Oligotex Direct mRNA Mini Kit (QIAGEN). The mRNA was loaded onto a denaturing 0.8% agarose formaldehyde gel and transferred onto a nylon membrane (Roche, Mannheim, Germany). The membrane was blocked for 30 min at 65°C with hybridization buffer, digoxigenin Easy Hyb (Roche), and hybridized overnight at 65°C with riboprobes for BDNF and cyclophilin. After washing, a 1-h blocking step was performed. The membrane was incubated with anti-Dig-AP (Roche; 1:20,000). The mRNA was detected with CDP-Star ready-to-use (Roche) and exposed to X-ray films.

WESTERN BLOT
------------

Western blot with the antibody CNC1, which is directed against Loop II/III of α~1~ 1.2, the central Ca~V~1.2 subunit, was performed as previously described ([@B18]; [@B9]). Briefly, tissue samples were extracted with 3× sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer at 90°C for 5 min before SDS-PAGE in 7.5% polyacrylamide gels, transfer to polyvinylidene difluoride (PVDF) membranes, blocking with 10% milk powder and detection with CNC1 and horseradish peroxidase-coupled protein A. Tubulin with an anti-tubulin monoclonal mouse antibody (Santa Cruz sc-5286, Dallas, TX, USA) was detected in parallel at the lower part of the blot to ensure equal loading when indicated.

DATA ANALYSIS
-------------

### ABR waveform amplitude analysis

The ABR waveforms were analyzed for consecutive amplitude deflections (waves), each wave consisting of a starting negative (n) peak and the following positive (p) peak. Peak amplitudes of ABR waves I and III were extracted in the present study and defined as follows: wave I: I~n~ - I~p~ (0.9--2 ms), wave III: III~n~ - III~p~ (3.3--4.1 ms). A customized program was used for the extraction of ABR peaks based on the definitions given above. ABR peak-to-peak, or wave amplitude growth functions were constructed for individual ears based on the extracted peaks for increasing stimulus levels. All ABR wave amplitude growth functions were calculated for increasing stimulus levels with reference to the ABR thresholds (from -20 to a maximum of 75 dB above threshold before noise exposure and from -20 to a maximum of 55 dB above threshold after noise exposure). For illustration purpose, ABR wave amplitude growth functions as shown in **Figures [3A](#F3){ref-type="fig"},[B](#F3){ref-type="fig"},[D](#F3){ref-type="fig"},[E](#F3){ref-type="fig"}** and **[6A](#F6){ref-type="fig"},[B](#F6){ref-type="fig"}** were first linearly interpolated to the resolution of 1 data point/dB and then smoothed by a moving zero-phase Gaussian filter with a window length of 9 data points. The ABR waveforms shown in the inset of the figures were smoothed by a moving zero-phase Gaussian filter with a window length of 5 data points (0.5 ms).

### Statistical analysis

Unless otherwise stated, all data were presented as group mean with SD or with standard error of the mean (SEM). Differences of the means were compared for statistical significance either by Student's *t*-test, one-way, or two-way ANOVA tests. The ANOVA tests were followed by multiple *t*-tests with Bonferroni--Holm's adjustment of α levels. Statistical significance was tested at the level α = 0.05, and resulting *p* values are reported in the legends. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001; n.s., not significant.

RESULTS
=======

CONDITIONAL DELETION OF Ca~V~1.2 DRIVEN BY THE Pax2 AND Egr2 PROMOTERS
----------------------------------------------------------------------

To circumvent embryonic lethality of mice globally lacking Ca~V~1.2, Ca~V~1.2 loxP/loxP (or floxed) mice ([@B43]) were either mated to Pax2::Cre mice ([@B34]) or to Egr2::Cre mice ([@B53]).

As predicted for the usage of Cre under control of the Pax2 promoter ([@B34]; [@B63]), Ca~V~1.2^Pax2^ KO mice exhibited a deletion of Ca~V~1.2 in the cochlea, brainstem, and cerebellum, but not in the auditory cortex. This was detected by Western blot analysis \[**Figure [1A](#F1){ref-type="fig"}**, *n* = 10 cochleae (5 mice), 2 brainstem (2 mice), 2 cerebella (2 mice), 2 auditory cortex (2 mice); experiments done in triplicate\]. The deletion of Ca~V~1.2 in spiral ganglion neurons (SGNs; [@B55]) was confirmed by immunohistochemistry (**Figure [1B](#F1){ref-type="fig"}**, Ca~V~1.2, red). No Ca~V~1.2 staining was observed in Ca~V~1.2^Pax2^ KO animals in comparison to control littermates (**Figure [1B](#F1){ref-type="fig"}**, red).

![**Tissue-specific deletion of Ca~V~1. 2 in Ca~V~1.2^Pax2^ KO and Ca~V~1.2^Egr2^ KO mice.** **(A)** Western blot for Ca~V~1.2 protein (230 and 190 kDa proteolytic product) in mouse cochlea (Co), brainstem (BS), cerebellum (Ce), and cortex (Cx) from control and Ca~V~1.2^Pax2^ KO mice. No Ca~V~1.2 protein was detected in tissues from KO mice, with the exception for the cortex where the Cre-mediated recombination does not occur \[*n* = 10 cochleae (5 mice), 2 brainstem (2 mice), 2 cerebella (2 mice), 2 auditory cortex (2 mice); experiments done in triplicate\]. **(B)** Immunofluorescent labeling of Ca~V~1.2 in spiral ganglion neurons from control mice (left), shown at higher magnification (insert) and Ca~V~1.2^Pax2^ KO mice (right) using an antibody against Ca~V~1.2 (red). Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; blue). **(C)** Western blot for Ca~V~1.2 protein (230 kDa) and tubulin (60 kDa) in control and Ca~V~1.2^Egr2^ KO mice confirming the deletion of Ca~V~1.2 in the superior olivary complex (SOC; *n* = 3 control mice, 3 KO mice; experiments done in triplicate).](fnmol-06-00020-g001){#F1}

Usage of Cre under the control of the Egr2 promoter leads to a knock-out of Ca~V~1.2 in the SOC forming part of the auditory brainstem ([@B53]; [@B36]; [@B39]). This was confirmed by Western blot of the SOC (*n* = 3 control mice, 3 KO mice; experiments done in triplicate) where no Ca~V~1.2 expression was detected (**Figure [1C](#F1){ref-type="fig"}**).

HEARING FUNCTION IN Ca~V~1.2 MOUSE LINES
----------------------------------------

To test whether the lack of Ca~V~1.2 in the cochlea or brainstem affects hearing function at adult stages, ABR and DPOAE in 2- to 4-month-old mice were measured.

For the Ca~V~1.2^Pax2^ mice, no significant difference was observed compared to controls for click-evoked ABR thresholds (**Figure [2A](#F2){ref-type="fig"}**, Ca~V~1.2^Pax2^ control: 15.6 ± 2.97 dB SPL; Ca~V~1.2^Pax2^ KO: 16.2 ± 2.71 dB SPL; *n* = 16 ears, 8 mice each, two-sided Student's *t*-test: *p* = 0.556) or tone-burst evoked ABR thresholds (**Figure [2B](#F2){ref-type="fig"}**, Ca~V~1.2^Pax2^ control: *n* = 7--8 ears, 7--8 mice; Ca~V~1.2^Pax2^ KO: *n* = 6--8 ears, 6--8 mice, two-way ANOVA, *p* = 0.890). Similar results were obtained for the Ca~V~1.2^Egr2^ mouse line for click-evoked stimuli (**Figure [2E](#F2){ref-type="fig"}**, Ca~V~1.2^Egr2^ control: 13.2 ± 2.20, *n* = 16 ears, 8 mice; Ca~V~1.2^Egr2^ KO: 14.7 ± 4.28, *n* = 18 ears, 9 mice, two-sided Student's *t*-test: *p* = 0.204) and tone-burst evoked ABR thresholds (**Figure [2F](#F2){ref-type="fig"}**, Ca~V~1.2^Egr2^ control: *n* = 12--13 ears, 8--9 mice; Ca~V~1.2^Egr2^ KO: *n* = 13 ears, 9 mice, two-way ANOVA, *p* = 0.132).

![**No deterioration of ABR thresholds and OHC function in Ca~V~1.2^Pax2^ KO and Ca~V~1.2^Egr2^ KO mice.** **(A)** Mean ± SD click-evoked ABR (click-ABR) thresholds for Ca~V~1.2^Pax2^ control (black horizontal dash, single ear thresholds as white circles) and Ca~V~1.2^Pax2^ KO mice (red horizontal dash, single ear thresholds as red squares). Thresholds were not significantly different (two-sided Student's *t*-test: *p* = 0.556) between KO mice (16.2 ± 2.71, *n* = 16 ears, 8 mice) and control (15.6 ± 2.97, *n* = 16 ears, 8 mice). **(B)** Mean ± SD tone-burst-evoked ABR (f-ABR) thresholds for Ca~V~1.2^Pax2^ KO mice (red) and controls (white). Thresholds were not significantly different (two-way ANOVA, *p* = 0.890) between KO mice (*n* = 6--8 ears, 6--8 mice) and controls (*n* = 7--8 ears, 7--8 mice). **(C)** Mean ± SD DPOAE thresholds for Ca~V~1.2^Pax2^ control mice (control, white) and Ca~V~1.2^Pax2^ KO mice (KO, red). Thresholds were not significantly different (two-way ANOVA: *p* = 0.452) between KO mice (*n* = 4 ears, 4 mice) and controls (*n* = 4 ears, 4 mice). **(D)** Mean ± SD DPOAE amplitude I/O function evoked by stimulus f2 = 11.3 kHz for Ca~V~1.2^Pax2^ KO mice (red) and controls (white) showing no significant difference (two-way ANOVA: *p* = 0.158) between KO mice (*n* = 4 ears, 4 mice) and controls (*n* = 4 ears, 4 mice). **(E)** Mean ± SD click-ABR thresholds for Ca~V~1.2^Egr2^ control mice (black horizontal dash, single ear thresholds as white circles) and Ca~V~1.2^Egr2^ KO (green horizontal dash, single ear thresholds as green squares). Thresholds were not significantly different (two-sided Student's *t*-test: *p* = 0.204) between KO mice (14.7 ± 4.28, *n* = 18 ears, 9 mice) and controls (13.2 ± 2.20, *n* = 16 ears, 8 mice). **(F)** Mean ± SD f-ABR thresholds for Ca~V~1.2^Egr2^ KO mice (green) and controls (white). Thresholds were not significantly different (two-way ANOVA, *p* = 0.132) between KO mice (*n* = 13 ears, 9 mice) and controls (*n* = 12--13 ears, 8--9 mice). **(G)** Mean ± SD DPOAE thresholds for Ca~V~1.2^Egr2^ KO mice (green) and controls (Ca~V~1.2^Egr2^ control, white). Thresholds were not significantly different (two-way ANOVA: *p* = 0.195) between KO mice (*n* = 16--18 ears, 9 mice) and controls (*n* = 14--15 ears, 8 mice). **(H)** Mean ± SD DPOAE amplitude I/O function evoked by stimulus f2 = 11.3 kHz for Ca~V~1.2^Egr2^ KO mice (green) and controls (white) showing no significant difference (two-way ANOVA: *p* = 0.566) between KO mice (*n* = 16--18 ears, 9 mice) and controls (*n* = 14--15 ears, 8 mice).](fnmol-06-00020-g002){#F2}

Since OHC electromotility codetermines the sound-evoked neural potentials at threshold ([@B11]), DPOAE were measured as an objective indicator of OHC function. The DPOAE thresholds (**Figures [2C](#F2){ref-type="fig"},[G](#F2){ref-type="fig"}**) and the input/output (I/O) function of emission amplitudes evoked by stimulus frequency of 11.3 kHz (**Figures [2D](#F2){ref-type="fig"},[H](#F2){ref-type="fig"}**), the frequency showing the best hearing sensitivity for the mice, were found to be similar between control and Ca~V~1.2^Pax2^ KO mice (Ca~V~1.2^Pax2^ control: *n* = 4 ears, 4 mice; Ca~V~1.2^Pax2^ KO: *n* = 4 ears, 4 mice, two-way ANOVA, *p* = 0.452) and Ca~V~1.2^Egr2^ KO (Ca~V~1.2^Egr2^ control: *n* = 14--15 ears, 8 mice; Ca~V~1.2^Egr2^ KO: *n* = 16--18 ears, 9 mice), indicating that loss of Ca~V~1.2 did not influence motility of OHCs.

The click-evoked ABR waveform amplitudes are expected to change proportionally to the size of discharge rates and number of synchronously firing auditory nerve (AN) fibers ([@B19]). We, therefore, analyzed ABR wave I (**Figures [3A](#F3){ref-type="fig"},[D](#F3){ref-type="fig"}**), reflecting the summed activity of the AN fibers, and ABR wave III (**Figures [3B](#F3){ref-type="fig"},[E](#F3){ref-type="fig"}**), corresponding to the SOC ([@B29]), in the two Ca~V~1.2 mutant mouse lines where Ca~V~1.2 is missing either in the cochlea or in parts of the auditory brainstem (**Figure [1](#F1){ref-type="fig"}**). In Ca~V~1.2^Pax2^ mice, but not in Ca~V~1.2^Egr2^ mice, a stronger decline of ABR wave I was observed beginning at 50 dB above threshold (**Figure [3A](#F3){ref-type="fig"}**, Ca~V~1.2^Pax2^ control: *n* = 3--6 ears, 3--6 mice; Ca~V~1.2^Pax2^ KO: *n* = 5--9 ears, 3--6 mice; two-way ANOVA, *p* = 0.048, *post hoc* one-sided Student's *t*-test: *p* = 0.049 at 65 dB above threshold, no Bonferroni--Holm's adjustment for multiple testing; **Figure [3D](#F3){ref-type="fig"}**, Ca~V~1.2^Egr2^ control: *n* = 12--13 ears, 7 mice; Ca~V~1.2^Egr2^ KO: *n* = 7--11 ears, 4--8 mice; two-way ANOVA: *p* = 0.784). No significant differences were observed for the amplitudes of ABR wave III between KO mice (both Ca~V~1.2^Pax2^ KO and Ca~V~1.2^Egr2^ KO) and the respective controls (**Figures [3B](#F3){ref-type="fig"},[E](#F3){ref-type="fig"}**).

![**Reduction of ABR wave I amplitudes and unaltered ABR wave III amplitudes in Ca~V~1.2^Pax2^ KO mice.** **(A)** Mean ± SEM click-evoked ABR wave I amplitude growth function for Ca~V~1.2^Pax2^ control (control, black line, and gray area) and Ca~V~1.2^Pax2^ KO mice (KO, red squares). ABR wave I amplitudes were significantly different (two-way ANOVA, *p* = 0.048) between KO (*n* = 5--9 ears, 3--6 mice) and controls (*n* = 3--6 ears, 3--6 mice), particularly at 65 dB above threshold (*post hoc* one-sided Student's *t*-test: *p* = 0.049, no Bonferroni--Holm's adjustment for multiple testing). The black and red waveforms in the inset depict representative ABR traces measured from one individual ear of a Ca~V~1.2^Pax2^ control and a KO mouse, respectively, evoked at the level of 65 dB above the hearing threshold. The leading negative (n) and following positive (p) peak corresponded to wave I are indicated by an upward and a downward pointing arrow head associated with symbols "I~n~" and "I~p~" respectively. **(B)** Mean ± SEM click-evoked ABR wave III amplitude growth function for controls and Ca~V~1.2^Pax2^ KO mice. ABR wave III amplitudes were not significantly different (two-way ANOVA, *p* = 0.639) between KO (*n* = 2--5 ears, 2--4 mice) and controls (*n* = 3 ears, 2 mice). The leading negative (n) and following positive (p) peak corresponded to wave III are indicated by arrow heads and marked "III~n~" and "III~p~" respectively. **(C)** Mean synaptic ribbon number ± SD are not significantly different (two-way ANOVA, *p* = 0.260) between control and Ca~V~1.2^Pax2^ KO mice in apical, medial, and midbasal cochlear turns (control: *n* = 4 cochleae, 3 mice; KO: *n* = 3 cochleae, 3 mice). **(D)**Mean ± SEM click-evoked ABR wave I amplitude growth function for Ca~V~1.2^Egr2^ KO mice (green squares) and controls (Ca~V~1.2^Egr2^ control, black and gray area). ABR wave I amplitudes were not significantly different (two-way ANOVA, *p* = 0.784) between KO (*n* = 7--11 ears, 4--8 mice) and controls (*n* = 12--13 ears, 7 mice). The black and green waveforms in the inset depict representative ABR traces measured from one individual ear of a Ca~V~1.2^Egr2^ control mouse and KO mouse, respectively, evoked at the level of 65 dB above the hearing threshold. **(E)** Mean ± SEM click-evoked ABR wave III amplitude growth function for Ca~V~1.2^Egr2^ KO mice and controls. ABR wave III amplitudes were not significantly different (two-way ANOVA, *p* = 0.281) between KO (*n* = 9--12 ears, 5--7 mice) and controls (*n* = 10--11 ears, 6 mice). **(F)** Mean ± SD IHC ribbon counts for Ca~V~1.2^Pax2^ control (control, white bars) and Ca~V~1.2^Pax2^ KO mice (KO, green bars) in apical, medial, and midbasal cochlear turns. No significant difference (two-way ANOVA, *p* = 0.446) between the number of ribbons in control and Ca~V~1.2^Egr2^ KO mice (control: *n* = 3 cochleae, 3 mice; KO: *n* = 3 cochleae, 3 mice).](fnmol-06-00020-g003){#F3}

Synaptic ribbons are known to be an accurate metric of the afferent innervation of IHCs ([@B22]) that drive postsynaptic AN fibers by a large releasable transmitter pool ([@B28]). The number of synaptic ribbons in the Ca~V~1.2^Pax2^ and Ca~V~1.2^Egr2^ mouse lines (**Figures [3C](#F3){ref-type="fig"},[F](#F3){ref-type="fig"}**) was not significantly different observed along the different cochlear turns \[apical: 2--7 kHz, medial: 7--16 kHz, and midbasal: \>17 kHz ([@B32])\] between the mutant lines and their respective controls (**Figure [3C](#F3){ref-type="fig"}**, control: *n* = 4 ears, 3 mice and Ca~V~1.2^Pax2^ KO: *n* = 3 ears, 3 mice, two-way ANOVA: *p* = 0.260; **Figure [3F](#F3){ref-type="fig"}**, controls: *n* = 3 ears, 3 mice, Ca~V~1.2^Egr2^ KO: *n* = 3 ears, 3 mice, two-way ANOVA: *p* = 0.446).

ACOUSTIC TRAUMA EFFECT ON HEARING FUNCTION IN CONDITIONAL Ca~V~1.2 MUTANTS
--------------------------------------------------------------------------

We studied a possible role of Ca~V~1.2 during noise damage by comparing ABR thresholds between control and Ca~V~1.2^Pax2^ KO and Ca~V~1.2^Egr2^ KO mice after exposing them for 1 h to broadband noise (4--16 kHz) of 120 dB SPL. Hearing thresholds were analyzed by ABR to click stimulus 7--11 days after noise exposure (**Figure [4](#F4){ref-type="fig"}**).

![**Mild loss of click-ABR threshold in Ca~V~1.2^Pax2^ KO mice after noise exposure.** **(A)** Mean ± SD click-ABR threshold losses for Ca~V~1.2^Pax2^ controls (black horizontal dash, 45.3 ± 9.51, *n* = 16 ears, 8 mice, single ear threshold losses as white circles) and Ca~V~1.2^Pax2^ KO mice (red horizontal dash, 30.9 ± 8.87, *n* = 16 ears, 8 mice, single ear threshold losses as red squares) 7 days after noise exposure showing a significantly milder threshold loss (14.5 dB difference; two-sided Student's *t*-test: *p* \< 0.001) in Ca~V~1.2^Pax2^ KO mice. **(B)** Mean ± SD click-ABR threshold losses for Ca~V~1.2^Egr2^ controls (black horizontal dash, 21.6 ± 16.8, *n* = 13 ears, 7 mice, single ear threshold losses as white circles) and Ca~V~1.2^Egr2^ KO mice (green horizontal dash, 17.2 ± 12.9, *n* = 16 ears, 8 mice, single ear threshold losses as green squares) 7--11 days after noise exposure, showing similar threshold loss (4.4 dB difference; two-sided Student's *t*-test: *p* = 0.431). Dotted lines at 0 dB represent no threshold loss after noise exposure.](fnmol-06-00020-g004){#F4}

All noise-exposed animals (controls and KOs) showed significant ABR threshold losses for click stimuli (**Figures [4A](#F4){ref-type="fig"},[B](#F4){ref-type="fig"}**; **Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**).

###### 

Auditory brainstem response thresholds for Ca~V~1.2^Pax2^ mouse line evoked by click stimuli.

                           Click-ABR threshold (dB SPL)   Significance         
  ------------------------ ------------------------------ -------------------- --------
  Ca~V~1.2^Pax2^ control   15.6 ± 2.97 (16/8)             60.9 ± 8.90 (16/8)   \*\*\*
  Ca~V~1.2^Pax2^ KO        16.2 ± 2.71 (16/8)             47.1 ± 8.84 (16/8)   \*\*\*
  Significance             n.s.                           \*\*\*               

Mean ± SD (no. of ears/no. of mice); \*\*\*

p

\< 0.001 (two-sided

t

-test); n.s., not significant.

###### 

Auditory brainstem response thresholds for Ca~V~1.2^Egr2^ mouse line evoked by click stimuli.

                           Click-ABR threshold (dB SPL)   Significance          
  ------------------------ ------------------------------ --------------------- --------
  Ca~V~1.2^Egr2^ control   13.2 ± 2.20 (16/8)             34.8 ± 15.70 (13/7)   \*\*\*
  Ca~V~1.2^Egr2^ KO        14.7 ± 4.28 (18/9)             31.9 ± 12.80 (16/8)   \*\*\*
  Significance             n.s.                           n.s.                  

Mean ± SD (no. of ears/no. of mice); \*\*\*

p

\< 0.001 (two-sided

t

-test); n.s., not significant.

However, ABR thresholds to click stimuli were significantly lower in noise-exposed Ca~V~1.2^Pax2^ KO mice in comparison to noise-exposed controls after 7 days (**Figure [4A](#F4){ref-type="fig"}**; **Table [1](#T1){ref-type="table"}**, comparison between genotypes at 7 days post noise). On the contrary, no differences were observed between control and Ca~V~1.2^Egr2^ KO mice. Reduced vulnerability of click-ABR threshold loss appeared instantaneously and was observed already at the first day after exposure (**Figure [5](#F5){ref-type="fig"}**), indicating that Ca~V~1.2 deletion may control a key event for threshold loss already shortly after the induction of trauma.

![**Preservation of click-ABR thresholds in Ca~V~1.2^Pax2^ KO mice after noise exposure.** Mean ± SD click-ABR threshold losses for control and Ca~V~1.2^Pax2^ KO mice before noise exposure, after noise exposure at the same day, 1 day, 3 days, and 7 days, showing a significant differences in threshold losses (two-way ANOVA, *p* \< 0.001) between control (14--16 ears, 7--8 mice) and KO (16 ears, 8 mice). Significant differences in threshold loss were observed at 3 days (*post hoc* two-sided Student's *t*-test: *p* = 0.007, Bonferroni--Holm's adjustment for multiple testing) and 7 days (*post hoc* two-sided Student's *t*-test: *p* \< 0.001, Bonferroni--Holm's adjustment for multiple testing) after noise exposure.](fnmol-06-00020-g005){#F5}

These data suggest that Ca~V~1.2 deletion in the cochlea, but not in the brainstem, protects against noise.

Since significant differences in hearing thresholds were observed between Ca~V~1.2^Pax2^ control and KO mice 7--11 days after noise exposure, click-evoked ABR wave amplitude growth functions were compared between control and Ca~V~1.2^Pax2^ KO 7 days after noise exposure for latencies corresponding to the AN (wave I) and SOC (wave III; [@B29]). After noise exposure, both ABR wave I (**Figure [6A](#F6){ref-type="fig"}**, Ca~V~1.2^Pax2^ control: *n* = 5--11 ears, 5--8 mice; Ca~V~1.2^Pax2^ KO: *n* = 6--13 ears, 5--8 mice; two-way ANOVA, *p* = 0.004, *post hoc* one-sided Student's *t*-test: *p* = 0.038 at 35 dB above threshold, Bonferroni--Holm's adjustment for multiple testing; *p* = 0.026 at 40 dB above threshold, no Bonferroni--Holm's adjustment for multiple testing) and ABR wave III amplitudes in Ca~V~1.2^Pax2^ KO mice (**Figure [6B](#F6){ref-type="fig"}**, Ca~V~1.2^Pax2^ control: *n* = 3--10 ears, 3--6 mice; Ca~V~1.2^Pax2^ KO: *n* = 3--7 ears, 3--4 mice; two-way ANOVA, *p* = 0.013) were less reduced when compared to the controls at high stimulation levels of sound intensity (\>30 dB above thresholds).

![**Less reduction of ABR wave I and wave III amplitudes in Ca~V~1.2^Pax2^ KO mice after noise exposure.** **(A)** Mean ± SEM click-evoked ABR wave I amplitude growth function for Ca~V~1.2^Pax2^ KO mice (red squares) and controls (control, black line and gray area) 7 days after noise exposure. ABR wave I amplitudes were significantly different (two-way ANOVA, *p* = 0.004) between KOs (*n* = 6--13 ears, 5--8 mice) and controls (*n* = 5--11 ears, 5--8 mice), particularly at 35 dB (*post hoc* one-sided Student's *t*-test: *p* = 0.038, Bonferroni--Holm's adjustment for multiple testing) and 40 dB (*post hoc* one-sided Student's *t*-test: *p* = 0.026, no Bonferroni--Holm's adjustment for multiple testing) above threshold. The black and red waveforms in the inset depict ABR traces measured from one individual ear of a Ca~V~1.2^Pax2^ control and KO mouse, respectively, evoked at the level of 40 dB above the hearing threshold. The leading negative (n) and following positive (p) peak corresponded to wave I are indicated by arrow heads and marked "I~n~" and "I~p~" respectively. **(B)** Mean ± SEM click-evoked ABR wave III amplitude growth function for Ca~V~1.2^Pax2^ KO mice and controls. ABR wave III amplitudes were significantly different (two-way ANOVA, *p* = 0.013) between KOs (*n* = 3--7 ears, 3--4 mice) and controls (*n* = 3--10 ears, 3--6 mice). The leading negative (n) and following positive (p) peak corresponded to wave III are indicated by arrow heads and marked "III~n~" and "III~p~" respectively. **(C)** Mean ribbon counts ± SD of control and Ca~V~1.2^Pax2^ KO before and 7 days after noise exposure showing reduction of the number of ribbons between control mice before and after noise exposure at all three cochlear turns, and was statistically significant at the medial and the midbasal turns (one-way ANOVA, apical turn *p* = 0.060, medial turn *p* = 0.026, midbasal turn *p* = 0.047). However, reduction is mainly observed in the control mice (before noise exposure: white bars, *n* = 4 cochleae, 4 mice; after noise exposure: gray bars, *n* = 3 cochleae, 3 mice; *post hoc* two-sided Student's *t*-test with no Bonferroni--Holm's adjustment for multiple testing for medial turn: *p* = 0.018 and midbasal turn: *p* = 0.045) but not in the Ca~V~1.2^Pax2^ KO mice (before noise exposure: red bars, *n* = 3 cochleae, 3 mice; after noise exposure: dark red bars, *n* = 3 cochleae, 3 mice; *post hoc* two-sided Student's *t*-test with no Bonferroni--Holm's adjustment for multiple testing for medial turn: *p* = 0.306 and midbasal turn: *p* = 0.773). Seven days after noise exposure, larger number of ribbons are observed in Ca~V~1.2^Pax2^ KO mice at all three cochlear turns and are significantly larger at the medial turn (*post hoc* two-sided Student's *t*-test with no Bonferroni--Holm's adjustment for multiple testing, *p* = 0.004) and midbasal turn (*post hoc* two-sided Student's *t*-test with no Bonferroni--Holm's adjustment for multiple testing, *p* = 0.023) compared to control mice.](fnmol-06-00020-g006){#F6}

The changes in the ABR wave I amplitude and the hearing thresholds observed in Ca~V~1.2^Pax2^ mutants were accompanied by an altered number of synaptic ribbons in the three cochlear regions (apical, medial, and midbasal). Ribbon numbers in noise exposed Ca~V~1.2^Pax2^ KO IHCs were slightly different in all cochlear turns 7 days after exposure compared with the ribbon numbers in Ca~V~1.2^Pax2^ KO mice, but were higher in comparison to noise-exposed control mice (**Figure [6C](#F6){ref-type="fig"}**).

Ca~V~1.2^Pax2^ KO MICE SHOW REDUCED BDNF LEVELS IN THE COCHLEA
--------------------------------------------------------------

We showed recently that BDNF controls the number of ribbon synapses in cochlear IHCs and that its absence protects against noise-induced damage ([@B63]). Most strikingly, L-VGCCs have been described to play a crucial role for activation of nerve growth factor responsiveness in the brain ([@B2]; [@B44]; [@B48]; [@B56]; [@B49]; [@B51]; [@B7]). We, therefore, analyzed BDNF levels in the cochleae of Ca~V~1.2^Pax2^ KO mice through real-time PCR and Northern blots using primers or riboprobes spanning the BDNF protein coding exon IX. The Ca~V~1.2^Pax2^ KO mice showed a reduced expression of BDNF mRNA by real-time PCR (**Figure [7A](#F7){ref-type="fig"}**, Ca~V~1.2^Pax2^ control: *n* = 11 mice; Ca~V~1.2^Pax2^ KO: *n* = 10 mice, two-sided Student's *t*-test: *p* = 0.006) and Northern blot (**Figures [7B](#F7){ref-type="fig"},[C](#F7){ref-type="fig"}**, Ca~V~1.2^Pax2^ control: *n* = 12 mice; Ca~V~1.2^Pax2^ KO: *n* = 11 mice, two-sided Student's *t*-test: *p* = 0.193 for 4.4 kb and *p* = 0.043 for 1.8 kb), confirming that BDNF expression is regulated by Ca~V~1.2 in the cochlea. The noise protection observed may thus be explained by the reduced BDNF levels when Ca~V~1.2 is deleted in the cochlea, similar to the situation in BDNF^Pax2^ KO mice ([@B63]).

![**Reduced expression of BDNF in the cochlea of Ca~V~1.2^Pax2^ KO mice.** **(A)** Real-time PCR of BDNF exon IX mRNA in the cochlea of control (white bar) and Ca~V~1.2^Pax2^ KO mice (red bar), expressed as a percentage of the control set to 100%, shows a significant reduction of the mRNA level in the KO mice (Ca~V~1.2^Pax2^ control: *n* = 11 mice; Ca~V~1.2^Pax2^ KO: *n* = 10 mice, two-sided Student's *t*-test: *p* = 0.006). **(B)** Northern blot of control and Ca~V~1.2^Pax2^ KO mice cochlea showing the two BDNF isoforms at 1.8 and 4.4 kb and cyclophilin as housekeeping gene at 0.8 kb. **(C)** Quantification of the Northern blot shows a significant reduction of the 1.8 kb BDNF mRNA isoform, but not the 4.4 kb isoform in the cochlea of Ca~V~1.2^Pax2^ KO mice (Ca~V~1.2^Pax2^ control, white bars: *n* = 12 mice; Ca~V~1.2^Pax2^ KO, red bars: *n* = 11 mice, two-sided Student's *t*-test: *p* = 0.193 for 4.4 kb and *p* = 0.043 for 1.8 kb). Data are expressed as a percentage of control set to 100%.](fnmol-06-00020-g007){#F7}

DISCUSSION
==========

We recently showed that lack of BDNF hampers IHC synapse physiology and hearing function while it protects against noise-induced hearing loss (NIHL; [@B63]). In the present study, we provide evidence that part of this crucial BDNF expression may be controlled by the L-VGCC Ca~V~1.2.

Ca~V~1.2 is expressed in SGN and efferent synapses ([@B54]) that originate in the olivocochlear system in the brainstem and terminate axo-dendritically on afferent type I fibers and axo-somatically on OHCs in the cochlea ([@B57]). The expression pattern of Ca~V~1.2 is mostly non-overlapping with that of another L-VGCC, Ca~V~1.3, that has been shown to play an essential role for hearing, since its deletion results in deafness ([@B35]).

Ca~V~1.2 knock-out mice are lethal at birth and thus, the role of Ca~V~1.2 in hearing function is elusive. Ca~V~1.2 is assumed to participate in altering synapse efficacy through transcriptional control of BDNF ([@B48]; [@B63]).

According to [@B56], Ca^2+^ influx through Ca~V~1.2 activates a Ca^2+^ responsive binding protein, CaRF, that acts as a *cis*-acting element on the BDNF exon IV promoter to control BDNF transcription after, e.g., stimulation by kainate. In this study, we analyzed mice with a conditional deletion of Ca~V~1.2 in the cochlea, with Cre recombinase controlled by the Pax2 promoter as recently described for the conditional BDNF KO mice in [@B63]. We, moreover, compared the effect of deletion of Ca~V~1.2 in the SOC using mice with Cre recombinase controlled by Egr2 promoter (Ca~V~1.2^Egr2^ KO mice).

By measuring ABR thresholds and DPOAE, where the DPOAE reflect the functionality of the OHCs, we found that both Ca~V~1.2^Pax2^ KO and Ca~V~1.2^Egr2^ KO mice do not display significant changes of thresholds and OHC function. This implies that Ca~V~1.2 expression in the cochlea and SOC might not be essential for maintenance of hearing thresholds and OHC function. Furthermore, we analyzed the ABR wave amplitudes, which reflect the number of synchronously firing neurons in distinct structures and nuclei along the ascending auditory pathway ([@B5]). Wave I amplitudes, corresponding to the neural activity from the AN fibers ([@B19]), of Ca~V~1.2^Pax2^ KO mice were found significantly reduced starting at 50 dB above threshold compared to the control mice. In contrast, wave III amplitudes, corresponding to the neural activity from the cochlear nucleus (CN) and the SOC in the lower brainstem ([@B29]), of the Ca~V~1.2^Pax2^ KO mice are unchanged. Also wave I and III amplitudes of Ca~V~1.2^Egr2^ KO mice appeared normal.

This may indicate that, similar to the role of BDNF ([@B63]), lack of Ca~V~1.2 in the cochlea hampers the function of the AN, but the phenotype appears to be less pronounced.

*Per contra* to what has been described for the BDNF conditional KO mice ([@B63]), we could not find significant differences in the number of ribbons in Ca~V~1.2^Pax2^ KO mice. Ribbon structure in IHC maintains a large ready releasable pool in IHCs and defines the reliability within spikes of auditory fibers ([@B4]). A reduced ABR wave I amplitude was found only at high sound intensities, suggesting that the lack of Ca~V~1.2 in the Ca~V~1.2^Pax2^ KO mice may alter the number of synchronously firing AN fibers that particularly respond to high sound intensities. Indeed, at least two different afferent fiber types exist: high spontaneous firing rate (SR) fibers with greater sensitivities (low-response thresholds) and low SR fibers with less sensitivity (high-response thresholds; [@B24], [@B25]). ABR thresholds, depending on the responses of high SR AN fibers, were not affected in Ca~V~1.2^Pax2^ KO mice, while AN responses at high intensities were found to be reduced. Thus, we hypothesize that Ca~V~1.2 in the cochlea might contribute to the neural responses of low SR AN fibers. Future studies may test this hypothesis.

It has been reported that prolonged noise exposure induces various types of hearing damage in rodents, including loss of threshold and disturbance of neural activity along the ascending auditory pathway ([@B22]; [@B63]; [@B37]; [@B46]). Recent studies suggested that the trigger of the loss of SGN in the cochlea, after an acoustic overstimulation, does not originate from IHCs but rather from IHC supporting cells. In particular, inner border and inner phalangeal cells have been proposed to be essential for neuronal survival after IHC damage ([@B61]). These supporting cell types have also been shown to express BDNF ([@B47]; [@B63]). Around 7--11 days after noise exposure, NIHL and a PTS were observed in both Ca~V~1.2^Pax2^ KO and Ca~V~1.2^Egr2^ KO mouse lines. However, the ABR threshold loss was significantly less pronounced in the Ca~V~1.2^Pax2^ KO mouse mutants than in the Ca~V~1.2^Egr2^ KO mice. This indicates that deletion of Ca~V~1.2 might reduce the vulnerability to acoustic trauma. A reduced vulnerability to acoustic trauma was also observed recently upon deletion of BDNF under the same Pax2 promoter as used here for Ca~V~1.2 deletion ([@B63]). A first hint that the phenotype of Ca~V~1.2^Pax2^ KO and BDNF^Pax2^ KO after acoustic trauma may be causally related is yielded by the observation that BDNF mRNA is partially reduced in the cochlea of Ca~V~1.2^Pax2^ KO mice. The loss of BDNF mRNA in Ca~V~1.2^Pax2^ KO cochlea mainly affected the short BDNF transcripts. Short and long BDNF transcripts result from alternative 3′ end processing of the BDNF transcripts at 3′ untranslated regions (3′UTRs). Distinct RNA sequences in these BDNF 3′UTRs are reported to differentially regulate neuronal activity changes through altered BDNF stability and translation of these BDNF mRNA isoforms ([@B23]). While we are far from understanding the role of different BDNF transcripts in the cochlea, we may conclude that Ca~V~1.2 controls short BDNF transcripts. A selected function of Ca~V~1.2 for short BDNF transcripts during its action on destabilization of IHC/afferent contacts during acoustic trauma, but not during BDNF-related retention of the IHC/afferent contacts in the intact system, may be tested in future studies. It has to be taken into consideration that the deletion of Ca~V~1.2 resulted in only 20--40% reduction of BDNF transcripts in the cochlea. This may explain a milder protecting phenotype than that found in the BDNF^Pax2^ KO mice. However, it cannot be ruled out that the protection against the noise-induced damage, when Ca~V~1.2 is deleted in the cochlea, is the result of selective impact on only a subpopulation of cells or the AN fibers.

In conclusion we show that Ca~V~1.2 deletion in the cochlea affects mainly an AN fiber type with high-response thresholds. Moreover, the current data demonstrate that the deletion of Ca~V~1.2 in the cochlea (Ca~V~1.2^Pax2^ mice) rather than the deletion of Ca~V~1.2 in the SOC (Ca~V~1.2^Egr2^ mice) can trigger a reduced vulnerability to acoustic trauma-induced auditory fiber loss. We provide evidence that this effect is linked to a Ca~V~1.2 function on maintaining expression of long or short BDNF transcripts, which in the cochlea may drive destabilization of IHCs/afferent contacts during acoustic trauma as already hypothesized in [@B63]. This destabilization of IHCs/afferents may originate from a Ca~V~1.2-related BDNF expression and release from supporting cells after cochlear injury. Further studies are on the way to analyze this aspect in more detail.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This work was supported by the Marie Curie Research Training Network CavNET MRTN-CT-2006-035367, the Deutsche Forschungsgemeinschaft DFG-Kni-316-4-1 and Hahn Stiftung (Index AG), and the NIH R01 AG017502. The authors thank PD Dr. med. Sven Moosmang (Institute of Pharmacology and Toxicology, TUM, Munich) who kindly provided the Ca~V~1.2 Floxed mice. We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Tübingen University.

[^1]: Edited by: *Nicola Maggio, The Chaim Sheba Medical Center, Israel*

[^2]: Reviewed by: *Sheriar Hormuzdi, University of Dundee, UK; Emilio Carbone, Department of Drug Science, Italy*

[^3]: ^†^Present address: *Annalisa Zuccotti, Department of Clinical Neurobiology, University Hospital and Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.*

[^4]: ^‡^*Annalisa Zuccotti, Sze C. Lee, and Dario Campanelli have contributed equally to this work.*
